Abstract: The present disclosure provides a method for testing an internal force increment of an arch bridge suspender by inertial measurement, including the following steps: (1) selecting a suspender to be tested with internal force increment, and mounting an acceleration sensing device or a speed sensing device at a lower edge of the suspender to be tested; (2) setting an appropriate sampling frequency and collecting signals; (3) processing information data collected in step (2) by using Formulas; and (4) recording a result of the information data processing and obtaining the internal force increment of the suspender. The method can obtain the internal force increment of the suspender by collecting acceleration or speed signals of the lower edge of the suspender and performing calculation from the signals. This method has the advantages of simple and convenient testing, high replicability and low test cost.

Abstract: Provided are use of a rare earth amino acid complex, a polylactic acid composition and a preparation method thereof. The rare earth amino acid complex is formed by complexing a rare earth metal ion with an amino acid; a rare earth element corresponding to the rare earth metal ion is one or more selected from the group consisting of lanthanum, cerium and samarium; and the amino acid is at least one selected from the group consisting of proline, L-phenylalanine, tyrosine and tryptophan.

Abstract: Use of Cistanche deserticola polysaccharide (CDP) in promoting the proliferation and differentiation of female germline stem cells (FGSCs) is provided. Specifically, the addition of CDP in an in vitro cultivation system can promote the proliferation and differentiation of FGSCs, and especially can enhance the in vitro directed differentiation of FGSCs into oocytes, which provides a new research reference for studying the generation of oocytes in vivo and in vitro and also brings a new hope for research on physiological infertility.

Abstract: A degradable regenerative medical material for promoting tissue in-situ regeneration and a preparation method therefor. The degradable regenerative medicine material is formed by means of chemically bonding Si, P, O and metallic elements containing calcium, and is a regular three-dimensional net structure the material of which having a nano-scale mesoporous structure is framework, and pores and micron-scale macropores that communicate with the pores are uniformly distributed in the regular three-dimensional net structure. The preparation method for the degradable regenerative medical material comprises the steps of mixing a sol, foaming, curing and calcining. The degradable regenerative medicine material has a huge specific surface area, powerful biological activity and high biological safety, has the effect of promoting cell proliferation, may induce the rapid regeneration of its own damaged tissue cells, and achieve an in-situ tissue repair function.

Abstract: Use of Cistanche deserticola polysaccharide (CDP) in promoting the proliferation and differentiation of female germline stem cells (FGSCs) is provided. Specifically, the addition of CDP in an in vitro cultivation system can promote the proliferation and differentiation of FGSCs, and especially can enhance the in vitro directed differentiation of FGSCs into oocytes, which provides a new research reference for studying the generation of oocytes in vivo and in vitro and also brings a new hope for research on physiological infertility.

Abstract: The methods disclosed herein include diagnosing a patient with MS, selecting a patient for further testing for MS, should the patient show elevated level of human IgG relative to an appropriate control. The methods also include differentiating subtypes of MS. The methods also include evaluating the efficacy of an MS drug or course of drug treatments, and/or treating MS. The methods include determining whether patients have elevated levels of IgG3-IgG1 immune complexes (which can include glycosylated IgG antibodies) in both blood and CSF. Methods also include diagnosing patients with primary-progressive MS (PPMS) and secondary-progressive MS (SPMS) where patients have higher levels of IgG3-IgG1 complexes in both CSF and blood, and reduced levels of albumin compared to patients with relapsing-remitting MS (RRMS).